Perrigo (PRGO) Non-Current Deferred Tax Liability (2013 - 2026)
Perrigo (PRGO) posted quarterly Non-Current Deferred Tax Liability of $153.5 million for Q1 2026, down 18.87% year-over-year from $189.2 million in Q1 2025, and down 9.12% quarter-over-quarter from $168.9 million in Q4 2025.
Perrigo (PRGO) Non-Current Deferred Tax Liability (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Non-Current Deferred Tax Liability for 14 consecutive years, with $153.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 18.87% year-over-year to $153.5 million; the TTM figure through Mar 2026 stood at $153.5 million (down 18.87% YoY), while the FY2025 annual figure was $168.9 million, down 16.88% from the prior year.
- Non-Current Deferred Tax Liability fell to $153.5 million in Q1 2026 per PRGO's latest filing, from $168.9 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $409.1 million in Q4 2022 and bottomed at $153.5 million in Q1 2026.
- Historically, Non-Current Deferred Tax Liability has averaged $264.0 million across 5 years, with a median of $238.9 million in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability jumped 68.35% — and 2024, when it sank 38.81%.
- Perrigo's Non-Current Deferred Tax Liability stood at $368.2 million in 2022, then slipped by 28.76% to $262.3 million in 2023, then fell by 22.53% to $203.2 million in 2024, then decreased by 16.88% to $168.9 million in 2025, then fell by 9.12% to $153.5 million in 2026.
- Business Quant data shows PRGO's Non-Current Deferred Tax Liability at $153.5 million in Q1 2026, $168.9 million in Q4 2025, and $194.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Perrigo | 1.91 Bn | 1.51 Bn | 313.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 146.70 Mn |
| Jun 27, 2026 | 146.70 Mn |
| Mar 28, 2026 | 153.50 Mn |
| Mar 28, 2026 | 153.50 Mn |
| Dec 31, 2025 | 168.90 Mn |
| Dec 31, 2025 | 168.90 Mn |
| Sep 27, 2025 | 194.40 Mn |
| Sep 27, 2025 | 194.40 Mn |
| Jun 28, 2025 | 206.80 Mn |
| Jun 28, 2025 | 206.80 Mn |
| Mar 29, 2025 | 189.20 Mn |
| Mar 29, 2025 | 189.20 Mn |
| Dec 31, 2024 | 203.20 Mn |
| Dec 31, 2024 | 203.20 Mn |
| Sep 28, 2024 | 213.80 Mn |
| Sep 28, 2024 | 213.80 Mn |
| Jun 29, 2024 | 211.70 Mn |
| Jun 29, 2024 | 211.70 Mn |
| Mar 30, 2024 | 247.70 Mn |
| Mar 30, 2024 | 247.70 Mn |